# AdvanTIG-202: Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIGIT Monoclonal Antibody Ociperlimab (BGB-A1217) in Participants With Previously Treated Recurrent or Metastatic Cervical Cancer

> **NCT04693234** · PHASE2 · COMPLETED · sponsor: **BeiGene** · enrollment: 178 (actual)

## Conditions studied

- Cervical Cancer

## Interventions

- **BIOLOGICAL:** Tislelizumab
- **BIOLOGICAL:** Ociperlimab

## Key facts

- **NCT ID:** NCT04693234
- **Lead sponsor:** BeiGene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-02-15
- **Primary completion:** 2022-06-16
- **Final completion:** 2023-08-31
- **Target enrollment:** 178 (ACTUAL)
- **Last updated:** 2025-04-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04693234

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04693234, "AdvanTIG-202: Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIGIT Monoclonal Antibody Ociperlimab (BGB-A1217) in Participants With Previously Treated Recurrent or Metastatic Cervical Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04693234. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*